European active surveillance of renal cell carcinoma study (E.A.S.E. RCC study)

European active surveillance of renal cell carcinoma study (E.A.S.E. RCC study) - EASE

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47206

Enrollment

Registered

2016-08-31

Start date

2017-07-02

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal cell carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: o Males or females, age >= 18 years. o Incidental diagnosis at imaging (ultrasonography, CT, MRI) of a solid renal mass

Exclusion criteria

Exclusion criteria: o Renal tumors with a non-RCC histology (sarcomas, lymphomas, etc.). o Tumor related symptoms at presentation. o Patients with known genetic diseases associated with RCC (e.g. Van Hippel Landau). o Patients unsuitable for biopsy due to need for concomitant anticoagulation or anti-platelet drug use which cannot be transiently discontinued. o Patients unsuitable for biopsy due to tumor location or small tumor size. o Patients with concurrent systemic treatment for another cancer. o Patients with estimated life expectancy

Design outcomes

Primary

Measure	Time frame
Primary endpoint is overall survival.	—

Secondary

Measure	Time frame
Secondary endpoints are tumor growth rate, progression rate, cancer-specific survival, progression-free survival, identification of clinical and pathological variables and molecular and genetic markers that correlate with growth rate and progression.	—

Countries

Netherlands

Outcome results